A randomised, open label phase III trial with nimotuzumab, an anti-epidermal growth factor receptor monoclonal antibody in the treatment of newly diagnosed adult glioblastoma - Westphal, Manfred; Geletneky, Karsten (European journal of cancer, 2015)
Gesehen am 27.09.2016